A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.
Sign Up to like & getrecommendations! Published in 2017 at "Trends in pharmacological sciences"
DOI: 10.1016/j.tips.2017.03.011
Abstract: There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the… read more here.
Keywords: tau; pathogenic tau; overview tauopathy; therapeutic strategies ... See more keywords
A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.
Sign Up to like & getrecommendations! Published in 2021 at "ACS nano"
DOI: 10.1021/acsnano.0c10690
Abstract: The hyperphosphorylated and aggregated tau accumulation represents a significant pathological hallmark of tauopathies including Alzheimer's disease (AD), which is highly associated with defective autophagy in neuronal cells. Autophagy-activating strategies demonstrate the therapeutic potential for AD… read more here.
Keywords: tau; autophagy activating; alzheimer disease; pathogenic tau ... See more keywords
β-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy
Sign Up to like & getrecommendations! Published in 2021 at "Life Science Alliance"
DOI: 10.26508/lsa.202101183
Abstract: GPCRs regulator, β-arrestin1, is increased in FTLD-tau patients, is required for β2-adrenergic receptor and metabotropic glutamate receptor 2-induced tau phosphorylation, promotes tau aggregation by impairing autophagy, and destabilizes microtubule dynamics, whereas genetic reduction in β-arrestin1… read more here.
Keywords: tau; pathogenic tau; gpcrs; promotes tauopathy ... See more keywords